Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The central nervous system (CNS) is a remarkably complex organ system, requiring an equally complex network of molecular pathways controlling the multitude of diverse, cellular activities. Gene expression is a critical node at which regulatory control of molecular networks is implemented. As such, elucidating the various mechanisms employed in the physiological regulation of gene expression in the CNS is important both for establishing a reference for comparison to the diseased state and for expanding the set of validated drug targets available for disease intervention. MicroRNAs (miRNAs) are an abundant class of small RNA that mediates potent inhibitory effects on global gene expression. Recent advances have been made in methods employed to study the contribution of these miRNAs to gene expression. Here we review these latest advances and present a methodological workflow from the perspective of an investigator studying the physiological regulation of a gene of interest. We discuss methods for identifying putative miRNA target sites in a transcript of interest, strategies for validating predicted target sites, assays for detecting miRNA expression, and approaches for disrupting endogenous miRNA function. We consider both advantages and limitations, highlighting certain caveats that inform the suitability of a given method for a specific application. Through careful implementation of the appropriate methodologies discussed herein, we are optimistic that important discoveries related to miRNA participation in CNS physiology and dysfunction are on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
MicroRNA targets in Drosophila
Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003) · Genome Biology · doi:10.1186/gb-2003-5-1-r1 · Cited by 3,597 · cited 2×
“The miRanda algorithm, unlike the previously described algorithms, does not rely solely on strict seed sequence complementarity for initial target site prediction (Betel et al., 2008; Enright et al., 2003; John et al., 2004).”
The RIN: an RNA integrity number for assigning integrity values to RNA measurements
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W., Granzow, M., & Ragg, T. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-3 · Cited by 2,623
The role of site accessibility in microRNA target recognition
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., & Segal, E. (2007) · Nature Genetics · doi:10.1038/ng2135 · Cited by 2,460 · cited 2×
“…algorithms include PITA, which takes into account target site secondary structure to determine accessibility of miRNAs to predicted target sites (Kertesz et al., 2007), and a pattern-based algorithm, rna22 (Miranda et al., 2006). rna22 utilizes pattern-recognition algorithms to capture sequence…”
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082 · cited 2×
“, 2006), phosphorothioate backbone modifications (Esau et al., 2006; Lennox and Behlke, 2010) or various design implementations shown to enhance potency, such as hairpin secondary structure (Vermeulen et al.”
Miranda, K. C., Huynh, T., Tay, Y., Ang, Y.-S., Tam, W.-L., Thomson, A. M., Lim, B., & Rigoutsos, I. (2006) · Cell · doi:10.1016/j.cell.2006.07.031 · Cited by 2,063
Argonaute HITS-CLIP decodes microRNA–mRNA interaction maps
Chi, S. W., Zang, J. B., Mele, A., & Darnell, R. B. (2009) · Nature · doi:10.1038/nature08170 · Cited by 1,791
Mayr, C., & Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.06.016 · Cited by 1,613 · cited 1×
“Two separate reports suggest that proliferating cells and some cancer cell lines may utilize alternative polyadenylation sites that favor shorter 3′-UTRs and therefore the potential elimination of functional miRNA target sites (Mayr and Bartel, 2009; Sandberg et al., 2008).”
Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites
Betel, D., Koppal, A., Agius, P., Sander, C., & Leslie, C. (2010) · Genome Biology · doi:10.1186/gb-2010-11-8-r90 · Cited by 1,592
Sempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., & Ambros, V. (2004) · Genome Biology · doi:10.1186/gb-2004-5-3-r13 · Cited by 1,578
BASKERVILLE, S., & BARTEL, D. P. (2005) · RNA · doi:10.1261/rna.7240905 · Cited by 1,508 · cited 2×
“…(Babak et al., 2004), along with strategies to label small RNA during first strand cDNA synthesis (Liu et al., 2004; Zhao et al., 2006), by PCR amplification with labeled primers (Baskerville and Bartel, 2005; Miska et al., 2004), and by poly(A) tailing using PAP (Shingara et al., 2005).”
MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.001 · Cited by 1,384
Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A., & Burge, C. B. (2008) · Science · doi:10.1126/science.1155390 · Cited by 1,349
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 1×
“Currently approved medications are not that effective and only modify symptoms; there is still no approved medication that alters the progression of the disease (Lahiri et al., 2003; Mangialasche et al., 2010; Raina et al., 2008; Schneider et al., 2011).”
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 2×
“Further, studies have also demonstrated that miRNAs are dysregulated in neurons of the AD brain and in the periphery and may contribute to disease etiology (Cogswell et al., 2008; Hébert et al., 2008; Lukiw, 2007; Nelson and Wang, 2010; Nunez-Iglesias et al., 2010; Schipper et al., 2007; Wang et al., 2008a) MiRNAs are…”
Morin, R. D., O’Connor, M. D., Griffith, M., Kuchenbauer, F., Delaney, A., Prabhu, A.-L., Zhao, Y., McDonald, H., Zeng, T., Hirst, M., et al. (2008) · Genome Research · doi:10.1101/gr.7179508 · Cited by 1,110
miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs
Mourelatos, Z., Dostie, J., Paushkin, S., Sharma, A., Charroux, B., Abel, L., Rappsilber, J., Mann, M., & Dreyfuss, G. (2002) · Genes & Development · doi:10.1101/gad.974702 · Cited by 1,105 · cited 2×
“The miRNA is then incorporated into a microribonucleoprotein (miRNP) complex (Mourelatos et al., 2002), also termed the RNA induced silencing complex (RISC) (Pratt and MacRae, 2009) [summarized in Fig.”
A novel and universal method for microRNA RT-qPCR data normalization
Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., & Vandesompele, J. (2009) · Genome Biology · doi:10.1186/gb-2009-10-6-r64 · Cited by 1,079 · cited 1×
“Distinct normalization strategies are recommended when performing global miRNA RT-qPCR analysis as compared to single miRNA analysis (Mestdagh et al., 2009).”
A microRNA array reveals extensive regulation of microRNAs during brain development
KRICHEVSKY, A. M., KING, K. S., DONAHUE, C. P., KHRAPKO, K., & KOSIK, K. S. (2003) · RNA · doi:10.1261/rna.5980303 · Cited by 1,040 · cited 2×
“Published methods also vary in the mechanism of small RNA labeling, including radioactive (Krichevsky et al., 2003), biotin (Sun et al., 2004) and fluorophore end-labeling (Babak et al., 2004), along with strategies to label small RNA during first strand cDNA synthesis (Liu et al., 2004; Zhao et…”
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues
Liu, C.-G., Calin, G. A., Meloon, B., Gamliel, N., Sevignani, C., Ferracin, M., Dumitru, C. D., Shimizu, M., Zupo, S., Dono, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403293101 · Cited by 948 · cited 2×
“, 2004), along with strategies to label small RNA during first strand cDNA synthesis (Liu et al., 2004; Zhao et al., 2006), by PCR amplification with labeled primers (Baskerville and Bartel, 2005; Miska et al.”
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 3×
“Further, studies have also demonstrated that miRNAs are dysregulated in neurons of the AD brain and in the periphery and may contribute to disease etiology (Cogswell et al., 2008; Hébert et al., 2008; Lukiw, 2007; Nelson and Wang, 2010; Nunez-Iglesias et al., 2010; Schipper et al., 2007; Wang et al., 2008a) MiRNAs are…”
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Microarray analysis of microRNA expression in the developing mammalian brain
Miska, E. A., Alvarez-Saavedra, E., Townsend, M., Yoshii, A., Šestan, N., Rakic, P., Constantine-Paton, M., & Horvitz, H. R. (2004) · Genome Biology · doi:10.1186/gb-2004-5-9-r68 · Cited by 803 · cited 2×
“…(Babak et al., 2004), along with strategies to label small RNA during first strand cDNA synthesis (Liu et al., 2004; Zhao et al., 2006), by PCR amplification with labeled primers (Baskerville and Bartel, 2005; Miska et al., 2004), and by poly(A) tailing using PAP (Shingara et al., 2005).”
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762 · cited 1×
“One transgenic strategy employs miRNA sponges (Ebert and Sharp, 2010; Ebert et al., 2007) that work in a similar manner to antisense oligonucleotide inhibitors.”
Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., & Caldas, C. (2010) · RNA · doi:10.1261/rna.1947110 · Cited by 689
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · cited 1×
“The disease itself is characterized by extracellular amyloid plaques consisting primarily of fibrillar amyloid-β (Aβ) peptide and intraneuronal neurofibrillary tangles composed of paired helical filaments of hyperphosphorylated tau (Nelson et al., 2009).”
In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes
Kloosterman, W. P., Wienholds, E., de Bruijn, E., Kauppinen, S., & Plasterk, R. H. A. (2006) · Nature Methods · doi:10.1038/nmeth843 · Cited by 599
Sequence-specific inhibition of small RNA function
Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020098 · Cited by 584 · cited 2×
“These inhibitors generally incorporate chemical modifications to enhance stability and hybridization strength in the form of 2′-O-methylation (Hutvágner et al., 2004), LNA (Ørom et al., 2006), phosphorothioate backbone modifications (Esau et al., 2006; Lennox and Behlke, 2010) or various design…”
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551 · cited 1×
“Elements in the APP mRNA 5′-UTR also mediate posttranscriptional regulation (Lahiri et al., 2005; Rogers et al., 1999, 2002).”
Self-citationCerebellar neurodegeneration in the absence of microRNAs
Schaefer, A., O'Carroll, D., Tan, C. L., Hillman, D., Sugimori, M., Llinas, R., & Greengard, P. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070823 · Cited by 498 · cited 24×
“In vivo delivery of miRNA modulators to the CNS is still difficult but direct cortical or intraventricular injection of modified synthetic molecules (Krützfeldt et al., 2007) or transgeneexpressing viral particles is an option.”
InfluentialKrol, J., Busskamp, V., Markiewicz, I., Stadler, M. B., Ribi, S., Richter, J., Duebel, J., Bicker, S., Fehling, H. J., Schübeler, D., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.039 · Cited by 470
Conditional Loss of Dicer Disrupts Cellular and Tissue Morphogenesis in the Cortex and Hippocampus
Davis, T. H., Cuellar, T. L., Koch, S. M., Barker, A. J., Harfe, B. D., McManus, M. T., & Ullian, E. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4815-07.2008 · Cited by 447 · cited 3×
“One strategy has been to globally reduce miRNA production by conditional deletion of Dicer in the CNS (Davis et al., 2008; Hébert et al., 2010; Konopka et al., 2010; Schaefer et al., 2007).”
Concordant Regulation of Translation and mRNA Abundance for Hundreds of Targets of a Human microRNA
Hendrickson, D. G., Hogan, D. J., McCullough, H. L., Myers, J. W., Herschlag, D., Ferrell, J. E., & Brown, P. O. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000238 · Cited by 418 · cited 1×
“Recent studies suggest that mRNA destabilization is the primary mechanism by which miRNA regulatory interactions reduce protein output (Guo et al., 2010; Hendrickson et al., 2009).”
Sethi, P., & Lukiw, W. J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.04.052 · Cited by 409
Probing microRNAs with microarrays: tissue specificity and functional inference
BABAK, T., ZHANG, W., MORRIS, Q., BLENCOWE, B. J., & HUGHES, T. R. (2004) · RNA · doi:10.1261/rna.7119904 · Cited by 385 · cited 2×
“, 2004) and fluorophore end-labeling (Babak et al., 2004), along with strategies to label small RNA during first strand cDNA synthesis (Liu et al.”
A biochemical approach to identifying microRNA targets
Karginov, F. V., Conaco, C., Xuan, Z., Schmidt, B. H., Parker, J. S., Mandel, G., & Hannon, G. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709971104 · Cited by 371 · cited 2×
“…specific anti-AGO antibodies (Ikeda et al., 2006; Nelson et al., 2007) to pull down RISC complexes comprising AGO effectors, miRNA guides, and mRNA targets (Beitzinger et al., 2007; Easow et al., 2007; Hendrickson et al., 2008; Karginov et al., 2007; Landthaler et al., 2008; Wang et al., 2010a).”
Benes, V., & Castoldi, M. (2010) · Methods · doi:10.1016/j.ymeth.2010.01.026 · Cited by 361
MicroRNA Loss Enhances Learning and Memory in Mice
Konopka, W., Kiryk, A., Novak, M., Herwerth, M., Parkitna, J. R., Wawrzyniak, M., Kowarsch, A., Michaluk, P., Dzwonek, J., Arnsperger, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3030-10.2010 · Cited by 306 · cited 24×
“In vivo delivery of miRNA modulators to the CNS is still difficult but direct cortical or intraventricular injection of modified synthetic molecules (Krützfeldt et al., 2007) or transgeneexpressing viral particles is an option.”
InfluentialIsolation of microRNA targets by miRNP immunopurification
Easow, G., Teleman, A. A., & Cohen, S. M. (2007) · RNA · doi:10.1261/rna.563707 · Cited by 301 · cited 2×
“…specific anti-AGO antibodies (Ikeda et al., 2006; Nelson et al., 2007) to pull down RISC complexes comprising AGO effectors, miRNA guides, and mRNA targets (Beitzinger et al., 2007; Easow et al., 2007; Hendrickson et al., 2008; Karginov et al., 2007; Landthaler et al., 2008; Wang et al., 2010a).”
RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain
NELSON, P. T., BALDWIN, D. A., KLOOSTERMAN, W. P., KAUPPINEN, S., PLASTERK, R. H. A., & MOURELATOS, Z. (2006) · RNA · doi:10.1261/rna.2258506 · Cited by 297
Rogers, J. T., Leiter, L. M., McPhee, J., Cahill, C. M., Zhan, S.-S., Potter, H., & Nilsson, L. N. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6421 · Cited by 290 · cited 1×
“Elements in the APP mRNA 5′-UTR also mediate posttranscriptional regulation (Lahiri et al., 2005; Rogers et al., 1999, 2002).”
Identification of human microRNA targets from isolated argonaute protein complexes
Beitzinger, M., Peters, L., Zhu, J. Y., Kremmer, E., & Meister, G. (2007) · RNA Biology · doi:10.4161/rna.4.2.4640 · Cited by 287
An optimized isolation and labeling platform for accurate microRNA expression profiling
SHINGARA, J., KEIGER, K., SHELTON, J., LAOSINCHAI-WOLF, W., POWERS, P., CONRAD, R., BROWN, D., & LABOURIER, E. (2005) · RNA · doi:10.1261/rna.2610405 · Cited by 260
MiR-107 is Reduced in Alzheimer's Disease Brain Neocortex: Validation Study
Nelson, P. T., & Wang, W.-X. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091603 · Cited by 222 · cited 2×
“crosslinking) to ensure that transient interactions are not lost during the IP step (Nelson et al., 2010).”
Hendrickson, D. G., Hogan, D. J., Herschlag, D., Ferrell, J. E., & Brown, P. O. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002126 · Cited by 178 · cited 2×
“…specific anti-AGO antibodies (Ikeda et al., 2006; Nelson et al., 2007) to pull down RISC complexes comprising AGO effectors, miRNA guides, and mRNA targets (Beitzinger et al., 2007; Easow et al., 2007; Hendrickson et al., 2008; Karginov et al., 2007; Landthaler et al., 2008; Wang et al., 2010a).”
RNA oxidation in Alzheimer disease and related neurodegenerative disorders
Nunomura, A., Hofer, T., Moreira, P. I., Castellani, R. J., Smith, M. A., & Perry, G. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0508-1 · Cited by 148
Autism, Alzheimer disease, and fragile X
Sokol, D. K., Maloney, B., Long, J. M., Ray, B., & Lahiri, D. K. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166dc7 · Cited by 141 · cited 4×
“New putative biomarkers, therapeutic strategies and targets are being tested (Alley et al., 2010; Bailey et al., 2011; Cogswell et al., 2008; Ray et al., 2011a) and are needed for successful intervention (Lahiri, 2011).”
InfluentialSelf-citationTechnical variables in high-throughput miRNA expression profiling: much work remains to be done
NELSON, P., WANG, W., WILFRED, B., & TANG, G. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.03.012 · Cited by 92 · cited 1×
“These experiments can be technically challenging and contain certain pitfalls of which investigators should be cognizant (Nelson et al., 2008).”
Cited by
The emerging roles of microRNAs in CNS injuries
Bhalala, O. G., Srikanth, M., & Kessler, J. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.67 · Cited by 248
Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366336 · Cited by 198
“We and others have begun to describe the contributions that miRNAs bring to the post-transcriptional control of APP expression (34, 35).”
BackgroundLong, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518241 · Cited by 187
Self-citationLong, J. M., Maloney, B., Rogers, J. T., & Lahiri, D. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0266-3 · Cited by 141
Self-citationLopez, J. P., Fiori, L. M., Gross, J. A., Labonte, B., Yerko, V., Mechawar, N., & Turecki, G. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000941 · Cited by 103
“…many target prediction algorithms that are easily accessed and generally successful in identifying likely target interactions, recent analyses on both protein and RNA expression have shown that bioinformatic predictions capture high levels of false positives and negatives (Long and Lahiri, 2012).”
BackgroundMethodInfluential
Metadata
- Authors
- Long, J. M., & Lahiri, D. K.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 235
- Issue
- 2
- Pages
- 402-418
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2042374359
- Cited by
- 43
- References
- 48
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.